BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 15508442)

  • 1. [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
    Jin CD; Yamamoto T; Nakamura M; Arai I; Kishin R; Xing X; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1511-5. PubMed ID: 15508442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
    Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
    Ishii T; Marumo K
    Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens.
    Katsumata K; Tomioka H; Sumi T; Yamashita S; Takagi M; Kato F; Nakamura R; Koyanagi Y; Aoki T; Kato K
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):155-60. PubMed ID: 12647017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].
    Fan XY; Uchida H; Iwaki K; Kai S; Shibata K; Ohta M; Kitano S
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):957-9. PubMed ID: 17565266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
    Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
    Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
    Oie S; Ono M; Yano H; Maruyama Y; Terada T; Yamada Y; Ueno T; Kojiro M; Hirano K; Kuwano M
    Int J Oncol; 2006 Dec; 29(6):1469-78. PubMed ID: 17088986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
    Kamoshida S; Shiogama K; Shimomura R; Inada K; Sakurai Y; Ochiai M; Matuoka H; Maeda K; Tsutsumi Y
    Oncol Rep; 2005 Nov; 14(5):1223-30. PubMed ID: 16211289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.
    Dou J; Iwashita Y; Sasaki A; Kai S; Hirano S; Ohta M; Kitano S
    Liver Int; 2005 Feb; 25(1):148-52. PubMed ID: 15698412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
    Kogure T; Ueno Y; Iwasaki T; Shimosegawa T
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):296-304. PubMed ID: 14689231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
    Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
    Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
    Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.